ClinicalTrialsFinder

Ipilimumab N01 Clinical Trials in Beijing, Beijing Municipality

1 recruitingBeijing, Beijing Municipality, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Colorectal, CancerBRAF V600ESintilimab+4 more
Tianjin Medical University Cancer Institute and Hospital49 enrolled4 locationsNCT07506109